x

Search for a clinical trial

* (*) mandatory field

A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC) - ES (completed)

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Bayer ag
    • Phase : II
Last update: August 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.